Q3 2024 Xvivo Perfusion AB Earnings Call Transcript
Key Points
- Xvivo Perfusion AB (XVIPF) reported a 41% organic growth in sales for Q3 2024, with sales reaching 191 million SEK.
- The company achieved a significant improvement in EBITA, demonstrating scalability in their revenue model.
- The US R trial showed high interest and activity, indicating strong potential for future growth.
- Xvivo Perfusion AB's heart and lung technologies are gaining acceptance, with promising clinical trial results.
- The company has a solid cash position of 450 million SEK, providing a strong financial foundation for future investments.
- Sales from services are lagging behind product sales, despite having a strong service offering.
- The abdominal business area experienced a slowdown in growth, attributed to a slow summer in Southern Europe.
- The company faces challenges in scaling up kidney transport sales in the US due to the need for additional clinical data.
- Reimbursement processes for the heart device in Europe are expected to take time, with variations across different countries.
- The services segment has underperformed, with a decline in volumes and the loss of two high-volume customers in 2023.
And welcome to Xvivo's earning call for the third quarter of 2024.
On the first light today's presentation that are sitting in the same room, Christopher Rosengard co and besides me, Kristoffer Nordstrom CFO of X Perfusion.
And with that, we turn to slide 2 the Q3 financials at a glance and, and I'm proud and happy to report that Q3 shows improving our top line as well as EBITA compared to the same quarter last year, even though we have continued and we will continue to invest in the organization for for future growth. Sales came in at 191 million, which is the 41% organic growth and their data shows an improvement to 21%.
The growth for is main Forex is mainly coming from higher PS activity during the quarter. Another growth that we see in this quarter is the US R trial where we are seeing very high interest to join the trial as well as well as very high activity in the trial during the summer months.
And Kristoffer Nordstrom, our Chief Financial Officer will get into the details on sale, gross margin avatar and the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
